The effect of an endothelin antagonist on blood pressure in a rat model of preeclampsia

Gayle Olson, George Saade, Irina Buhimschi, Kristof Chwalisz, Robert E. Garfield

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

OBJECTIVE: We attempted to determine the role of endothelin in a previously characterized animal model of preeclampsia by studying the effect of a specific endothelin antagonist, BQ123, on blood pressure. STUDY DESIGN: A preeclampsia-like condition was induced by infusing pregnant rats with the nitric oxide synthase inhibitor N(G)-nitro-L-arginine methyl ester. Osmotic minipumps were inserted subcutaneously into timed pregnant Harlan-Sprague- Dawley rats on day 17 of pregnancy (term, 22 days). The pumps were loaded to continuously deliver either vehicle (control group) or N(G)-nitro-L-arginine methyl ester 50 mg/d, either alone or with BQ123 at 0.5 mg/d. In a similar but separate experiment, the dose of BQ123 was increased to 1 mg/d. Blood pressure was measured with the tail-cuff method before pump insertion and then daily until postpartum day 2. RESULTS: Except for a decrease on the day after pump insertion, BQ123 0.5 mg/d had no significant effect on the hypertension induced by N(G)-nitro-L-arginine methyl ester. At the higher dose, however, BQ123 significantly attenuated the increase in blood pressure induced by N(G)-nitro-L-arginine methyl ester during most of the study period. CONCLUSION: The effect of nitric oxide inhibition can be successfully attenuated by the use of an endothelin antagonist, thereby supporting the role of endothelin in the hypertension described with the preeclampsia-like condition seen in pregnant rats.

Original languageEnglish (US)
Pages (from-to)638-641
Number of pages4
JournalAmerican Journal of Obstetrics and Gynecology
Volume181
Issue number3
DOIs
StatePublished - 1999

Fingerprint

Pre-Eclampsia
NG-Nitroarginine Methyl Ester
Blood Pressure
Endothelins
Hypertension
Nitric Oxide Synthase
Postpartum Period
Sprague Dawley Rats
Tail
Nitric Oxide
Animal Models
Endothelin Receptor Antagonists
cyclo(Trp-Asp-Pro-Val-Leu)
Pregnancy
Control Groups

Keywords

  • Endothelin
  • Nitric oxide inhibition
  • Preeclampsia

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynecology

Cite this

The effect of an endothelin antagonist on blood pressure in a rat model of preeclampsia. / Olson, Gayle; Saade, George; Buhimschi, Irina; Chwalisz, Kristof; Garfield, Robert E.

In: American Journal of Obstetrics and Gynecology, Vol. 181, No. 3, 1999, p. 638-641.

Research output: Contribution to journalArticle

Olson, Gayle ; Saade, George ; Buhimschi, Irina ; Chwalisz, Kristof ; Garfield, Robert E. / The effect of an endothelin antagonist on blood pressure in a rat model of preeclampsia. In: American Journal of Obstetrics and Gynecology. 1999 ; Vol. 181, No. 3. pp. 638-641.
@article{344e21dbffe745d6863ff72c054ac699,
title = "The effect of an endothelin antagonist on blood pressure in a rat model of preeclampsia",
abstract = "OBJECTIVE: We attempted to determine the role of endothelin in a previously characterized animal model of preeclampsia by studying the effect of a specific endothelin antagonist, BQ123, on blood pressure. STUDY DESIGN: A preeclampsia-like condition was induced by infusing pregnant rats with the nitric oxide synthase inhibitor N(G)-nitro-L-arginine methyl ester. Osmotic minipumps were inserted subcutaneously into timed pregnant Harlan-Sprague- Dawley rats on day 17 of pregnancy (term, 22 days). The pumps were loaded to continuously deliver either vehicle (control group) or N(G)-nitro-L-arginine methyl ester 50 mg/d, either alone or with BQ123 at 0.5 mg/d. In a similar but separate experiment, the dose of BQ123 was increased to 1 mg/d. Blood pressure was measured with the tail-cuff method before pump insertion and then daily until postpartum day 2. RESULTS: Except for a decrease on the day after pump insertion, BQ123 0.5 mg/d had no significant effect on the hypertension induced by N(G)-nitro-L-arginine methyl ester. At the higher dose, however, BQ123 significantly attenuated the increase in blood pressure induced by N(G)-nitro-L-arginine methyl ester during most of the study period. CONCLUSION: The effect of nitric oxide inhibition can be successfully attenuated by the use of an endothelin antagonist, thereby supporting the role of endothelin in the hypertension described with the preeclampsia-like condition seen in pregnant rats.",
keywords = "Endothelin, Nitric oxide inhibition, Preeclampsia",
author = "Gayle Olson and George Saade and Irina Buhimschi and Kristof Chwalisz and Garfield, {Robert E.}",
year = "1999",
doi = "10.1016/S0002-9378(99)70506-5",
language = "English (US)",
volume = "181",
pages = "638--641",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - The effect of an endothelin antagonist on blood pressure in a rat model of preeclampsia

AU - Olson, Gayle

AU - Saade, George

AU - Buhimschi, Irina

AU - Chwalisz, Kristof

AU - Garfield, Robert E.

PY - 1999

Y1 - 1999

N2 - OBJECTIVE: We attempted to determine the role of endothelin in a previously characterized animal model of preeclampsia by studying the effect of a specific endothelin antagonist, BQ123, on blood pressure. STUDY DESIGN: A preeclampsia-like condition was induced by infusing pregnant rats with the nitric oxide synthase inhibitor N(G)-nitro-L-arginine methyl ester. Osmotic minipumps were inserted subcutaneously into timed pregnant Harlan-Sprague- Dawley rats on day 17 of pregnancy (term, 22 days). The pumps were loaded to continuously deliver either vehicle (control group) or N(G)-nitro-L-arginine methyl ester 50 mg/d, either alone or with BQ123 at 0.5 mg/d. In a similar but separate experiment, the dose of BQ123 was increased to 1 mg/d. Blood pressure was measured with the tail-cuff method before pump insertion and then daily until postpartum day 2. RESULTS: Except for a decrease on the day after pump insertion, BQ123 0.5 mg/d had no significant effect on the hypertension induced by N(G)-nitro-L-arginine methyl ester. At the higher dose, however, BQ123 significantly attenuated the increase in blood pressure induced by N(G)-nitro-L-arginine methyl ester during most of the study period. CONCLUSION: The effect of nitric oxide inhibition can be successfully attenuated by the use of an endothelin antagonist, thereby supporting the role of endothelin in the hypertension described with the preeclampsia-like condition seen in pregnant rats.

AB - OBJECTIVE: We attempted to determine the role of endothelin in a previously characterized animal model of preeclampsia by studying the effect of a specific endothelin antagonist, BQ123, on blood pressure. STUDY DESIGN: A preeclampsia-like condition was induced by infusing pregnant rats with the nitric oxide synthase inhibitor N(G)-nitro-L-arginine methyl ester. Osmotic minipumps were inserted subcutaneously into timed pregnant Harlan-Sprague- Dawley rats on day 17 of pregnancy (term, 22 days). The pumps were loaded to continuously deliver either vehicle (control group) or N(G)-nitro-L-arginine methyl ester 50 mg/d, either alone or with BQ123 at 0.5 mg/d. In a similar but separate experiment, the dose of BQ123 was increased to 1 mg/d. Blood pressure was measured with the tail-cuff method before pump insertion and then daily until postpartum day 2. RESULTS: Except for a decrease on the day after pump insertion, BQ123 0.5 mg/d had no significant effect on the hypertension induced by N(G)-nitro-L-arginine methyl ester. At the higher dose, however, BQ123 significantly attenuated the increase in blood pressure induced by N(G)-nitro-L-arginine methyl ester during most of the study period. CONCLUSION: The effect of nitric oxide inhibition can be successfully attenuated by the use of an endothelin antagonist, thereby supporting the role of endothelin in the hypertension described with the preeclampsia-like condition seen in pregnant rats.

KW - Endothelin

KW - Nitric oxide inhibition

KW - Preeclampsia

UR - http://www.scopus.com/inward/record.url?scp=0032876291&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032876291&partnerID=8YFLogxK

U2 - 10.1016/S0002-9378(99)70506-5

DO - 10.1016/S0002-9378(99)70506-5

M3 - Article

VL - 181

SP - 638

EP - 641

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 3

ER -